Alvotech upgraded by Citigroup with a new price target
$ALVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citigroup upgraded Alvotech from Sell to Neutral and set a new price target of $10.00 from $5.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $18.00 | Buy | UBS |
| 1/29/2024 | $10.00 → $17.00 | Equal Weight → Overweight | Barclays |
| 10/20/2023 | $5.00 → $10.00 | Sell → Neutral | Citigroup |
| 9/21/2023 | $10.00 | Equal Weight | Barclays |
| 9/7/2022 | $10.00 | Equal-Weight | Morgan Stanley |
| 9/6/2022 | $12.00 → $5.00 | Buy → Sell | Citigroup |
REYKJAVIK, Iceland, May 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities Healthcare Conference 2025, which will be held in Las Vegas, Nevada, May 13-15, 2025. Members of the management team will host one-on-one meetings at the conference. Alvotech will also be participating in a fireside chat on Wednesday, May 14, 2025, at 11:40 am-12:10 pm EDT (15:40-16:10 GMT / 17:40-18:10 CET). A live audio webcast of the fireside chat will also be available to the general public and can be accessed at https://investors.a
Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in top line revenue and $200-280 million adjusted EBITDA, following acquisition of proposed biosimilar to CimziaAlvotech will conduct a business update conference call and live webcast on Thursday May 8, 2025, at 8:00 am ET (1
REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO) (the "Company") a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on the Company's product revenues in 2025. Alvotech manufactures its biosimilars in Iceland, a country which currently faces the minimum tariff of 10% on goods imported to the U.S. A 10% tariff on pharmaceuticals would raise the cost of biosimilars from Alvotech
UBS initiated coverage of Alvotech with a rating of Buy and set a new price target of $18.00
Barclays upgraded Alvotech from Equal Weight to Overweight and set a new price target of $17.00 from $10.00 previously
Citigroup upgraded Alvotech from Sell to Neutral and set a new price target of $10.00 from $5.00 previously
6-K - Alvotech (0001898416) (Filer)
6-K - Alvotech (0001898416) (Filer)
6-K - Alvotech (0001898416) (Filer)
SC 13G/A - Alvotech (0001898416) (Subject)
SC 13D/A - Alvotech (0001898416) (Subject)
SC 13G/A - Alvotech (0001898416) (Subject)
Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in top line revenue and $200-280 million adjusted EBITDA, following acquisition of proposed biosimilar to CimziaAlvotech will conduct a business update conference call and live webcast on Thursday May 8, 2025, at 8:00 am ET (1
REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio of the conference call will be webcast and available to members of the news media, investors, and the general public. Information on how
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in 2024 was $108.3 million compared to negative $291 million in 2023Submissions in major global markets were made in 2024 for three new proposed biosimilars. All applications have been subsequently accepted by the relevant regulatory authorities.Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm GMT). REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company
REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty pharma and healthcare sectors. He was most recently a director and highly ranked equities analyst at Barclays, covering US specialty pharma and with Alvotech in his portfolio. He served previously
REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB's ("Xbrane") R&D operations and a biosimilar candidate (the "Acquisition"), further expanding Alvotech's development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane's R&D operations based in Campus Solna, at the Karolinska Institute outside Stockholm, Sweden, as well as the biosimilar candidate XB003, referencing Cimzia® (certolizumab pegol). Xbrane retains other
REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer. Christina succeeds Sandra Casaca, who is leaving the company as a part of other organizational changes. Christina Siniscalchi has for over ten years served in senior quality positions for Alvogen and its manufacturing site in Norwich, NY, most recently as Alvogen's Chief Quality Officer. "We thank Sandra for her valuable contribution to Alvotech, as she successfully steered ou
Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:
Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:
Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification: